Just like our namesake Arbutus, a healing plant native to North America, we are leveraging our growing innovative portfolio of assets to focus our efforts on treating and curing conditions with unmet medical need.

About Arbutus Specialized in virology. Focused on growth. We are a clinical-stage biopharmaceutical company with deep virology expertise and an unwavering focus on curing conditions with unmet medical need.

All Arbutus clinical trials are conducted in compliance with the Declaration of Helsinki and the ICH Guideline for Good Clinical Practice HBV Learn about our three-pronged Suppress, Reduce, Boost approach to HBV.

Pursuing a cure for HBV through multiple, complementary mechanisms.. Recognizing that monotherapy approaches are unlikely to be successful in promoting functional cure in patients with cHBV, we are taking a three-pronged approach that combines compounds with complementary mechanisms of action to suppress viral DNA, reduce viral antigens and boost the host immune system.

At Arbutus, we are passionate about our mission and actively seeking collaborators and licensing opportunities within anti-viral diseases.

Nov 15, 2024 · At Arbutus, we regularly publish posters and presentations on our dynamic pipeline of assets.

AB-101 AB-101 is our oral PD-L1 inhibitor. The immune system of HBV chronically infected patients is tolerized to recognize the virus or infected cells.

At Arbutus, our village includes professionals with deep scientific, clinical, operational, and financial expertise. Our leadership team knows the path to market well, having played pivotal roles in the discovery, development, and commercialization of multiple approved antivirals.

Jun 6, 2024 · “Imdusiran consistently provides notable reductions in HBsAg prior to combining with other therapies, such as VTP-300, which may improve the response rates of these immunomodulatory approaches,” commented Dr. Karen Sims, Chief Medical Officer of …

Imdusiran (AB-729) Imdusiran is our RNAi therapeutic. Imdusiran is a subcutaneously-delivered RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral antigens, including hepatitis B surface antigen (HBsAg), which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus.